Helping You Heal with Honey Our Goal is Simple, Faster and Healthier Healing
Post-money valuation ⓘ
$23.9M
As of Jan 2022 · from SanMelix Laboratories Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$1,189,271
Across 2 rounds since 2019
Latest share price
$1.50
SanMelix Laboratories Common Stock 1 offering price
Financials
FY2017–FY2025 · from SEC filings · hover any figure for its source
$0
−$291K
2018
$0
−$227K
2019
$0
−$404K
2020
$53K
−$796K
2021
$50K
−$791K
2022
$8K
−$728K
2023
$8K
−$728K
2024
$49K
−$616K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Metric
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$52,695
$50,233
$7,904
$7,904
$49,228
Cost of goods sold
$0
$0
$0
$0
$13,626
$39,039
$6,212
$4,232
$12,166
Gross margin
—
—
—
—
74%
22%
21%
46%
75%
Net income
$0
-$290,979
-$226,917
-$404,179
-$796,389
-$790,675
-$727,781
-$727,782
-$616,108
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$298,229
$78,623
$51,318
$264,467
$339,829
$128,710
$67,201
$67,201
$26,889
Accounts receivable
$0
$0
$0
$0
$1,590
$839
$75
$75
$1,764
Total assets
$437,088
$95,038
$237,064
$460,947
$865,163
$323,674
$268,087
$268,087
$228,847
Short-term debt
$0
$4,272
$0
$0
$116,563
$150,000
$0
$0
$225,000
Long-term debt
$37,200
$0
$0
$29,744
$266,547
$219,667
$225,000
$225,000
$80,000
Total liabilities
$37,200
$4,272
$0
$29,744
$383,110
$369,667
$225,000
$225,000
$305,000
Other
Headcount
—
2
2
2
2
2
2
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.